Nanotechnology-based MRI contrast research

Imaging the Future: Nanotechnology based MRI Contrast for Safer Diagnosis

Knowledgepie team or lab

Knowledgepie Private Limited

Knowledgepie is a biotechnology company focused on innovative medical imaging solutions. The team is developing alternative MRI contrast agents to improve safety, sustainability, and clinical reliability.

Mission

To innovate safer contrast agents for cancer detection and prioritizing patient safety, enhancing diagnostic precision, and redefining global cancer care through advanced research, ethical practices, and collaboration with healthcare professionals.

Technology

Our developed technology is capped with biocompatible molecules and they form stable aqueous solutions, are non-toxic as certified by GLP and Genotoxicity studies. Synthesis is facile, aqueous, thermo-free, and single-step.

Our flagship product

Xeuj®

Our flagship product “Xeuj®” is a patented nanoparticle-based contrast agent, specifically targeting the renal impaired patients where GBCA is banned by FDA.

Applications

  • Magnetic Resonance Imaging (MRI) Enhancement: Improves visibility and contrast in MRI scans by altering tissue magnetic properties.
  • Detection and Characterization of Tumors: Crucial for distinguishing tumor tissues from healthy tissue, aiding in diagnosis and treatment planning.
  • Can be used for renal impaired patients also.
Applications of Xeuj MRI contrast agent

Uniqueness of Xeuj®

Environment friendly production

Environment Friendly

It is produced using a green route, which means it is environmentally friendly and has minimal impact on the ecosystem.

Advantages related to NSF

Advantages related to NSF

As an iron-based agent, it carries no risk of nephrogenic systemic fibrosis (NSF) unlike Gd-based contrast agents (GBCAs).

Make in India product

First ‘Make In India Product’

Will be ‘First to market’ ‘Make in India’ product in contrast agent market.

Latest news

View all news

Loading news…

Join us in the journey

Contact us today
+2 Patents
+12 Years of Research

Our Investment Partners